Apolipoprotein E gene polymorphism is related to metabolic abnormalities, but does not influence erythrocyte membrane lipid composition or sodium-lithium countertransport activity in essential hypertension.
The aim of this study was to analyze the influence of the apolipoprotein E (apoE) gene polymorphism on insulin resistance and plasma lipid composition of essential hypertensive patients. A secondary objective was to analyze if differences regarding plasma lipids had an effect on the erythrocyte membrane lipid composition and the activity of the erythrocyte membrane sodium-lithium countertransport. We studied 128 untreated nondiabetic essential hypertensive patients enrolled from our outpatient clinic. We considered as hyperinsulinemic all subjects having more than 80 mU/L of plasma insulin 120 minutes after a 75-g oral glucose intake. The number of hyperinsulinemic subjects among carriers of the epsilon4 allele was higher that in epsilon4 noncarrier subjects (13 of 19 v45 of 109, P < .05; odds ratio [OR], 3.08; confidence interval [CI], 0.99-10.57). Plasma insulin at baseline and plasma insulin and glucose at 120 minutes after overload was higher in carriers of the epsilon4 allele (respectively, 17.5 +/- 6.9 v 12.4 +/- 4.9 mU/L, P < .01; 111.9 +/- 39.9 v 88.7 +/- 48.2, P < .05; and 143.8 +/- 29.3 v 121.2 +/- 30.8 mg/dL, P < .005). Subjects with the epsilon4 allele had a plasma lipid profile more atherogenic than those without this allele. This profile was mainly characterized by higher levels of low-density lipoprotein (LDL) cholesterol (150.1 +/- 31.2 v 133.0 +/- 34.3 mg/dL, P < .05) and very-low-density lipoprotein (VLDL) triglycerides (134.7 +/- 85.5 v 99.2 +/- 68.8 mg/dL, P < .05) and by lower levels of high-density lipoprotein (HDL) cholesterol (41.8 +/- 10.7 v 50.0 +/- 14.7 mg/dL, P < .05). There were no differences between groups regarding erythrocyte membrane cholesterol or phospholipids composition and sodium-lithium countertransport (SLC) activity.
Unidad de Hipertensión y Lípidos del S de Medicina Interna, Seville, Spain.
P
P
Stiefel
C
C
Montilla
O
O
Muñiz-Grijalvo
R
R
García-Lozano
A
A
Alonso
M L
ML
Miranda
E
E
Pamies
J
J
Villar
D000328:Adult; D017920:Antiporters / Q000378:metabolism*; D053327:Apolipoprotein E4; D001057:Apolipoproteins E / Q000235:genetics*; D001786:Blood Glucose; D001794:Blood Pressure; D015992:Body Mass Index; D002784:Cholesterol / Q000032:analysis / Q000097:blood; D004910:Erythrocyte Membrane / Q000737:chemistry / Q000378:metabolism*; D005260:Female; D005787:Gene Frequency; D005838:Genotype; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000235:genetics / Q000378:metabolism; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008094:Lithium / Q000378:metabolism; D008297:Male; D008563:Membrane Lipids / Q000032:analysis*; D008875:Middle Aged; D010743:Phospholipids / Q000032:analysis; D011110:Polymorphism, Genetic; D012964:Sodium / Q000378:metabolism; D014280:Triglycerides / Q000097:blood
D017920:Antiporters; D053327:Apolipoprotein E4; D001057:Apolipoproteins E; D001786:Blood Glucose; D007328:Insulin; D008563:Membrane Lipids; D010743:Phospholipids; D014280:Triglycerides; C045885:sodium-lithium countertransporter; D002784:Cholesterol; D008094:Lithium; D012964:Sodium